Pediatrix Medical Group Announces Board and Executive Changes

Ticker: MD · Form: 8-K · Filed: Jan 14, 2025 · CIK: 893949

Sentiment: neutral

Topics: management-change, compensation, governance

Related Tickers: MD

TL;DR

Pediatrix board shakeup and exec comp changes announced.

AI Summary

Pediatrix Medical Group, Inc. announced on January 12, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for its key executives.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.

Risk Assessment

Risk Level: medium — Changes in leadership and compensation can indicate underlying issues or strategic shifts that may affect the company's future performance.

Key Numbers

Key Players & Entities

FAQ

Who are the specific officers or directors that have departed from Pediatrix Medical Group, Inc.?

The filing does not specify the names of the departing officers or directors, only that there have been departures.

When did the changes in directors and officers take effect?

The earliest event reported is dated January 12, 2025.

What specific changes were made to the compensatory arrangements of certain officers?

The filing indicates that there were changes to compensatory arrangements, but the specific details are not provided in this summary section.

How many new directors were elected to the board?

The filing states that directors were elected, but the exact number of newly elected directors is not specified.

What is the company's principal executive office address?

The principal executive offices are located at 1301 Concord Terrace, Sunrise, Florida, 33323.

Filing Stats: 1,319 words · 5 min read · ~4 pages · Grade level 13.2 · Accepted 2025-01-14 16:30:21

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pediatrix Medical Group, Inc. Date: January 14, 2025 By: /s/ Kasandra H. Rossi Kasandra H. Rossi Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing